Down‐regulated genes, including DGS3, DSC3, PKP1, EVPL, IVL, FLG, SPRR1A and SPRR1B, may be considered as new biomarkers in the therapeutics of metastatic melanoma, which might help us predict the potential metastatic capability of SKCM patients, thus provide earlier precautionary treatments. This evidence concerns the gene SPRR1A and metastatic melanoma.